{"title":"胸部外用替巴尼布林后大疱性皮疹","authors":"Jessica Kim, Onyebuchi Neita, Joseph M. Dyer","doi":"10.25251/skin.7.4.13","DOIUrl":null,"url":null,"abstract":"Tirbanibulin 1% ointment (Klisyri), an FDA-approved topical treatment for actinic keratosis, is advertised to serve as a first-in-class topical with high efficacy and low adverse effects compared to other field therapies. We report a case of severe bullous eruption associated with application of tirbanibulin in an adult female. Though application of tirbanibulin did resolve the actinic keratoses on the patient’s chest, the severe local skin reaction precludes future use of tirbanibulin in her case.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bullous Eruption after Off-label Use of Topical Tirbanibulin on the Chest\",\"authors\":\"Jessica Kim, Onyebuchi Neita, Joseph M. Dyer\",\"doi\":\"10.25251/skin.7.4.13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tirbanibulin 1% ointment (Klisyri), an FDA-approved topical treatment for actinic keratosis, is advertised to serve as a first-in-class topical with high efficacy and low adverse effects compared to other field therapies. We report a case of severe bullous eruption associated with application of tirbanibulin in an adult female. Though application of tirbanibulin did resolve the actinic keratoses on the patient’s chest, the severe local skin reaction precludes future use of tirbanibulin in her case.\",\"PeriodicalId\":74803,\"journal\":{\"name\":\"Skin (Milwood, N.Y.)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin (Milwood, N.Y.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25251/skin.7.4.13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin (Milwood, N.Y.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25251/skin.7.4.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bullous Eruption after Off-label Use of Topical Tirbanibulin on the Chest
Tirbanibulin 1% ointment (Klisyri), an FDA-approved topical treatment for actinic keratosis, is advertised to serve as a first-in-class topical with high efficacy and low adverse effects compared to other field therapies. We report a case of severe bullous eruption associated with application of tirbanibulin in an adult female. Though application of tirbanibulin did resolve the actinic keratoses on the patient’s chest, the severe local skin reaction precludes future use of tirbanibulin in her case.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
